1). Meier-Kriesche HU, Li ddS, Gruessner RW, Fung JJ, Bustami RT, Barr ML, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006; 6:1111–31.
Article
2). Kainz A, Heinze G, Korbély R, Schwarz C, Oberbauer R. Mycophenolate mofetil use is associated with prolonged graft survival after kidney transplantation. Transplantation. 2009; 88:1095–100.
Article
3). Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP. Trends in kidney transplantation in Australia and New Zealand, 1993–2004. Transplantation. 2007; 84:611–8.
Article
4). Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: metaanalysis and meta-regression of randomised trial data. BMJ. 2005; 331:810.
Article
5). Opelz G, Döhler B. Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation. 2009; 87:795–802.
Article
6). Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997; 63:39–47. Erratum in: Transplantation 1997;63: 618.
7). Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on longterm outcomes in kidney transplantation. Transplantation. 2005; 80(2 Suppl):S211–20.
Article
8). Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin North Am. 2001; 15:521–49.
Article
9). Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357:2601–14.
Article
10). Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis. 2002; 35:53–61.
Article
11). Humar A, Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006; 6:262–74.
Article
12). Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997; 10:86–124.
Article
13). San Juan R, Aguado JM, Lumbreras C, Diaz-Pedroche C, Lopez-Medrano F, Lizasoain M, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant. 2007; 7:964–71.
Article
14). Parasuraman R, Yee J, Karthikeyan V, del Busto R. Infectious complications in renal transplant recipients. Adv Chronic Kidney Dis. 2006; 13:280–94.
Article
15). Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998; 338:1741–51.
Article
16). Pourfarziani V, Panahi Y, Assari S, Moghani-Lankarani M, Saadat SH. Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in infections. Transplant Proc. 2007; 39:1237–40.
Article
17). Browne BJ. The tricontinental mycophenolate mofetil trial. Transplantation. 1996; 62:1697.
Article
18). Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009; 87:785–94.
Article
19). Hanvesakul R, Kubal C, Jham S, Sarkar E, Eardley K, Adu D, et al. Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients. Nephrol Dial Transplant. 2008; 23:4049–53.
Article
20). Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant. 2009; 9:1816–25.
Article
21). Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med. 1981; 70:405–11.
Article
22). Kim YK, Kim DW. Seroepidemiology of human cytomegalovirus in healthy adults measured by means of the anti-complement immunofluorescence technique. Korean J Infect Dis. 1992; 24:87–92. (김유겸, 유대원. Anticomplement Immunofluorescence 검사법을 이용한 건강한 성인의 Human Cytomegalovirus에 대한 항체가의 조사 연구. 감염 1992;24: 87–92.).
23). Kidney Disease. Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9(Suppl 3):S1–155.
24). Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006; 20:401–9.
Article
25). Jorge S, Guerra J, Santana A, Mil-Homens C, Prata MM. Mycophenolate mofetil: ten years' experience of a renal transplant unit. Transplant Proc. 2008; 40:700–4.
Article
26). Moreso F, Seron D, Morales JM, Cruzado JM, Gil-Vernet S, Perez JL, et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant. 1998; 12:198–205.